Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

SERD ZB716

An orally bioavailable selective estrogen receptor degrader/downregulator (SERD) and a structural analog of fulvestrant, with potential antineoplastic activity. Upon oral administration, SERD ZB-716 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	borestrant ERalpha-coregulator degrader ZB716 selective estrogen receptor alpha degrader ZB716 selective estrogen receptor degrader ZB716
Code name:	ZB 716 ZB-716 ZB716

SERD ZB716

Search NCI's Drug Dictionary